Shay Capital LLC Purchases New Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Shay Capital LLC purchased a new stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 51,300 shares of the company’s stock, valued at approximately $81,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Picton Mahoney Asset Management grew its stake in RAPT Therapeutics by 994.4% in the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after buying an additional 14,697 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in RAPT Therapeutics by 9.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock valued at $348,000 after buying an additional 18,558 shares during the last quarter. JPMorgan Chase & Co. grew its stake in RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after buying an additional 25,130 shares during the last quarter. Barclays PLC grew its stake in RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in RAPT Therapeutics by 4.9% in the 4th quarter. Geode Capital Management LLC now owns 716,937 shares of the company’s stock valued at $1,133,000 after buying an additional 33,758 shares during the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Stock Up 3.7%

NASDAQ RAPT opened at $0.84 on Friday. The company has a market capitalization of $110.92 million, a P/E ratio of -0.30 and a beta of -0.04. RAPT Therapeutics, Inc. has a 12-month low of $0.71 and a 12-month high of $4.83. The firm has a 50-day moving average price of $1.00 and a two-hundred day moving average price of $1.22.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.23. Equities analysts expect that RAPT Therapeutics, Inc. will post -2.14 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of RAPT Therapeutics in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, RAPT Therapeutics has an average rating of “Hold” and a consensus price target of $4.00.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.